CEDAR KNOLLS, NJ--(Marketwired - Jul 17, 2014) - MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market.
MYOS has engaged Cloud Pharmaceuticals, a cutting-edge pharmaceutical design company that creates new drugs and drug candidates and accelerates the development process by implementing new, innovative cloud computing technology, to initiate synthesis and design for small molecules relevant to Furin regulation and Janus Kinase 3 (JAK3) inhibition. Furin is a prototypical proprotein convertase that processes latent precursor proteins into their biologically active forms. Furin convertase plays a central role in the processing of myostatin to its biologically active form and therefore is a potentially important target for development of a therapeutic candidate. JAK3 is a tyrosine kinase which functions in signal transduction and is thought to be a factor in complex biochemical pathways central to inflammation. Candidates created in this research relationship will be the Company's first small molecules under consideration for further development as a treatment for age-related loss of muscle mass or sarcopenia in addition to cachexia.
Robert C. Ashton, Jr., M.D., Chief Medical Officer at MYOS commented, "This agreement underpins MYOS' commitment to focus on the expansion of our biotherapeutics development pipeline in important therapeutic areas of unmet need. We are excited to move forward in earnest with our agreement with Cloud Pharmaceuticals and utilize their high-performance drug design platform based on novel cloud computing resources with the goal of optimizing and expediting our drug development program. Importantly, Cloud Pharmaceuticals' unique technology has the ability to rapidly create and test novel molecules reducing both the time and cost of traditional drug development."
MYOS hopes to report on the initial target testing with Furin convertase by the end of 2015. Meanwhile MYOS will continue to assess and identify additional small molecule candidates for further design and evaluation within the Cloud Pharmaceuticals platform.
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. Cloud Pharmaceuticals accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners.
About MYOS Corporation
MYOS is a developmental stage biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™ (MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.
The Company's first commercial product based on Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ (MYO-T12®) and its effects on myostatin inhibition, including our research and development activities, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the successful completion of the research program with Cloud Pharmaceuticals described herein and the expansion of our biotherapeutic development pipeline, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Contact Information:
MYOS Corporation Investor and Media Contact:
Jenene Thomas
Investor Relations and Corporate Communications
(973) 509-0444